Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia.

21-hydroxylase deficiency adrenal insufficiency aldosterone dexamethasone fludrocortisone hydrocortisone plasma renin activity prednisolone

Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
10 Jan 2023
Historique:
received: 28 08 2022
revised: 06 11 2022
accepted: 30 11 2022
pubmed: 20 1 2023
medline: 31 1 2023
entrez: 19 1 2023
Statut: ppublish

Résumé

Poorly controlled salt-wasting (SW) congenital adrenal hyperplasia (CAH) patients often require high 9α-fluorocortisol doses as they show high levels of 17-hydroxyprogesterone (17OHP), which is a mineralocorticoid (MC)-receptor antagonist. We investigated the renin-angiotensin-aldosterone system in patients with SW-CAH receiving twice daily modified-release hydrocortisone (MR-HC, Efmody) compared with standard glucocorticoid (GC) therapy. Data were analyzed from the 6-month, phase 3 study of MR-HC (n = 42) versus standard GC therapy (n = 41). MC replacement therapy remained unchanged throughout the study. Blood pressure, serum potassium, serum sodium, plasma renin activity (PRA), and serum 17OHP and androstenedione concentrations were analyzed at baseline, 4, 12, and 24 weeks. The median serum 17OHP in the morning was significantly lower on MR-HC compared with standard GC at 24 weeks (2.5 nmol L-1 (IQR 8.3) versus 10.5 nmol L-1 (IQR 55.2), P = .001). PRA decreased significantly from baseline to 24 weeks in patients on MR-HC (0.83 ng L-1 s-1 (IQR 1.0) to 0.48 ng L-1 s-1 (IQR 0.61), P = .012) but not in patients on standard GC (0.53 ng L-1 s-1 (IQR 0.66) to 0.52 ng L-1 s-1 (IQR 0.78), P = .613). Serum sodium concentrations increased from baseline to 24 weeks in patients on MR-HC (138.8 ± 1.9 mmol L-1 to 139.3 ± 1.8 mmol L-1, P = .047), but remained unchanged on standard GC (139.8 ± 1.6 mmol L-1 to 139.3 ± 1.9 mmol L-1, P = .135). No significant changes were seen in systolic and diastolic blood pressure and serum potassium levels. 6 months of MR-HC therapy decreased PRA and increased sodium levels indicating a greater agonist action of the 9α-fluorocortisol dose, which may be due to the decreased levels of the MC-receptor antagonist 17OHP.

Identifiants

pubmed: 36654495
pii: 6991929
doi: 10.1093/ejendo/lvac006
pii:
doi:

Substances chimiques

Hydrocortisone WI4X0X7BPJ
Renin EC 3.4.23.15
Fludrocortisone U0476M545B
Glucocorticoids 0
17-alpha-Hydroxyprogesterone 68-96-2
Potassium RWP5GA015D
Sodium 9NEZ333N27

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Deutsche Forschungsgemeinschaft
Organisme : German Research Foundation
Organisme : NIH HHS
Pays : United States

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press on behalf of (ESE) European Society of Endocrinology.

Auteurs

Lea Tschaidse (L)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Nicole Reisch (N)

Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Munich, Germany.

Wiebke Arlt (W)

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, United Kingdom.

Aude Brac de la Perriere (A)

Hospices Civils de Lyon, Fédération d'Endocrinologie, Groupement hospitalier Est, Bron Cedex, France.

Angelica Linden Hirschberg (A)

Department of Women's and Children's Health, Karolinska Institutet and Department of Gynecology and Reproductive Medicine, Karolinska University Hospital, Stockholm, Sweden.

Anders Juul (A)

Department of Growth and Reproduction, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Ashwini Mallappa (A)

AstraZeneca, Gaithersburg, Maryland, United States.
National Institutes of Health Clinical Center, Bethesda, Maryland, United States.

Deborah P Merke (DP)

National Institutes of Health Clinical Center, Bethesda, Maryland, United States.
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda, Maryland, United States.

John D C Newell-Price (JDC)

University of Sheffield, Sheffield, United Kingdom.

Colin G Perry (CG)

Queen Elizabeth University Hospital, Glasgow, United Kingdom.

Alessandro Prete (A)

Institute of Metabolism and Systems Research (IMSR), University of Birmingham, Birmingham, United Kingdom.

D Aled Rees (DA)

Neuroscience and Mental Health Research Institute, School of Medicine, Cardiff University, Cardiff, United Kingdom.

Nike M M L Stikkelbroeck (NMML)

Radboud University Medical Center, Nijmegen, Netherlands.

Philippe A Touraine (PA)

University Hospitals Pitié Salpêtrière - Charles Foix, Center for Rare Endocrine and Gynecological Disorders, Paris, France.

Helen Coope (H)

Diurnal Ltd, Cardiff, United Kingdom.

John Porter (J)

Diurnal Ltd, Cardiff, United Kingdom.

Richard John M Ross (RJM)

University of Sheffield, Sheffield, United Kingdom.

Marcus Quinkler (M)

Endocrinology in Charlottenburg, Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH